The W43-MM1 mini-starburst ridge, a test for star formation efficiency models

Context: Star formation efficiency (SFE) theories are currently based on statistical distributions of turbulent cloud structures and a simple model of star formation from cores. They remain poorly tested, especially at the highest densities. Aims: We investigate the effects of gas density on the SFE through measurements of the core formation efficiency (CFE). With a total mass of $\sim2\times10^4$ M$_\odot$, the W43-MM1 ridge is one of the most convincing candidate precursor of starburst clusters and thus one of the best place to investigate star formation. Methods: We used high-angular resolution maps obtained at 3 mm and 1 mm within W43-MM1 with the IRAM Plateau de Bure Interferometer to reveal a cluster of 11 massive dense cores (MDCs), and, one of the most massive protostellar cores known. An Herschel column density image provided the mass distribution of the cloud gas. We then measured the 'instantaneous' CFE and estimated the SFE and the star formation rate (SFR) within subregions of the W43-MM1 ridge. Results: The high SFE found in the ridge ($\sim$6% enclosed in $\sim$8 pc$^3$) confirms its ability to form a starburst cluster. There is however a clear lack of dense cores in the northern part of the ridge, which may be currently assembling. The CFE and the SFE are observed to increase with volume gas density while the SFR steeply decreases with the virial parameter, $\alpha_{vir}$. Statistical models of the SFR may well describe the outskirts of the W43-MM1 ridge but struggle to reproduce its inner part, which corresponds to measurements at low $\alpha_{vir}$. It may be that ridges do not follow the log-normal density distribution, Larson relations, and stationary conditions forced in the statistical SFR models.Comment: 13 pages, 7 figures. Accepted by A&

Surveying activated sludge changes during acclimation with artificial wastewater

Many processes in the chemical and pharmaceutical industries generate wastewater containing organic toxic compounds and other kinds of xenobiotics. Usually, biological treatments are used to degrade a great quantity of these substances. However, most of the time, the microorganisms are not adapted and the treatment can be blocked. Therefore, the first step to make a continuous reactor operative is the acclimation, i.e., the adaptation of the microorganisms to a specific substrate. During this particular step of the process there is a selection and a multiplication of specialized microorganisms and physiological transformations can occur in their metabolic system. Furthermore, combining image processing techniques have already been successfully used to elucidate the activated sludge morphological changes for both aggregated and filamentous bacteria contents, during such processes. The experimental set-up is composed of an aerated reactor and a clarifier. The sludge is recycled from the clarifier by a peristaltic pump. The complete mixing inside the reactor is guaranteed by the diffusion of air from its bottom. The reactor was inoculated with biomass collected from a wastewater treatment plant and fed with an artificial wastewater based on meat extract. During acclimation, chemical parameters were measured in the influent, reactor and effluent, in order to verify the stability of the process. To complete the evaluation of the process, microscopy acquisition and image processing and analysis techniques were performed for aggregates and filamentous bacteria characterization for bright field, Gram and poly-β-hydroxybutyrate (PHB) staining images. The information extracted from those images allowed for aggregates and filamentous bacteria contents inspection, identification of PHB storing microorganisms and, gram-positive and gram-negative filamentous bacteria recognition. Figure 1 presents activated sludge samples at the beginning and at the end of the acclimation phase. It was found in this study that biomass changes during the acclimation phase could be effectively monitored, combining image analysis information and chemical parameters

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

Gemcitabine and oxaliplatin (GEMOX) are active as first-line therapy against advanced pancreatic cancer. This study aims to evaluate the activity and tolerability of this combination in patients refractory to standard gemcitabine (GEM). A total of 33 patients (median age of 57) were included with locally advanced and metastatic evaluable diseases, who had progressed during or following GEM therapy. The GEMOX regimen consisted of 1000 mg m−2 of GEM at a 100-min infusion on day 1, followed on day 2 by 100 mg m−2 of oxaliplatin at a 2-h infusion; a cycle that was given every 2 weeks. All patients received at least one cycle of GEMOX (median 5; range 1–29). Response by 31 evaluable patients was as follows: PR: 7/31(22.6%), s.d. ⩾8 weeks: 11/31(35.5%), s.d. <8 weeks: 1/31(3.2%), PD: 12/31(38.7%). Median duration of response and TTP were 4.5 and 4.2 months, respectively. Median survival was 6 months (range 0.5–21). Clinical benefit response was observed in 17/31 patients (54.8%). Grade III/IV non-neurologic toxicities occurred in 12/33 patients (36.3%), and grade I, II, and III neuropathy in 17(51%), 3(9%), and 4(12%) patients, respectively. GEMOX is a well-tolerated, active regimen that may provide a benefit to patients with advanced pancreatic cancer after progression following standard gemcitabine treatment

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

Targeting the epidermal growth factor receptor pathway in pancreatic cancer seems to be an attractive therapeutic approach. This study assessed the efficacy of cetuximab plus the combination of gemcitabine/oxaliplatin in metastatic pancreatic cancer. Eligible subjects had histological or cytological diagnosis of metastatic pancreatic adenocarcinoma. The primary end point was response according to RECIST. Patients received cetuximab 400 mg m−2 at first infusion followed by weekly 250 mg m−2 combined with gemcitabine 1000 mg m−2 as a 100 min infusion on day 1 and oxaliplatin 100 mg m−2 as a 2-h infusion on day 2 every 2 weeks. Between January 2005 and August 2006, a total of 64 patients (22 women (34%), 42 men (66%); median age 64 years (range 31–78)) were enrolled at seven study centres. On October 2007, a total of 17 patients were alive. Sixty-two patients were evaluable for baseline and 61 for assessment of response to treatment in an intention-to-treat analysis. Six patients had an incomplete drug combination within the first cycle of the treatment plan (n=4 hypersensitivity reactions to the first cetuximab infusion, n=2 refused to continue therapy). Reported grade 3/4 toxicities (% of patients) were leukopaenia 15%, anaemia 8%, thrombocytopaenia 10%, diarrhoea 7%, nausea 18%, infection 18% and allergy 7%. Cetuximab-attributable skin reactions occurred as follows: grade 0: 20%, grade 1: 41%, grade 2: 30% and grade 3: 10%. The intention-to-treat analysis of 61 evaluable patients showed an overall response rate of 33%, including 1 (2%) complete and 19 (31%) partial remissions. There were 31% patients with stable and 36% with progressive disease or discontinuation of the therapy before re-staging. The presence of a grade 2 or higher skin rash was associated with a higher likelihood of achieving objective response. Median time to progression was 118 days, with a median overall survival of 213 days. A clinical benefit response was noted in 24 of the evaluable 61 patients (39%). The addition of cetuximab to the combination of gemcitabine and oxaliplatin is well tolerated but does not increase response or survival in patients with metastatic pancreatic cancer